Tenaya Therapeutics awarded CEO Ali Faraz 122,000 shares at $0 per share and 732,500 derivative securities on September 10. The share award represented 22.6% of his resulting share holding, while the derivative award represented 100.0% of his resulting derivative securities holding, giving investors separate disclosed ownership measures.

Key Highlights

  • The transaction used code A, classifying both awards as grants.
  • The 122,000-share award represented about 22.6% of Ali Faraz’s resulting share holding.
  • The derivative-securities award represented about 100.0% of his resulting derivative securities holding.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) awarded Chief Executive Officer Ali Faraz 122,000 shares at $0 per share on September 10, bringing his resulting share holding to 539,782. The same transaction date also covered 732,500 derivative securities, with Faraz’s resulting holding listed at 732,500.

Shares and Derivative Securities Awarded

The award price was $0 per share. Tenaya Therapeutics also recorded an award of 732,500 derivative securities on September 10. Ali Faraz was the named recipient for both awards, and the transaction details separately state the resulting holdings for shares and derivative securities.

Resulting Ownership Percentages

The 122,000-share award represented about 22.6% of Faraz’s resulting share holding. The derivative-securities award represented about 100.0% of his resulting derivative-securities holding. Both percentages relate to the September 10 awards and use the holdings reported afterward.